Scientific Opinion on bovine lactoferrin
2012; Wiley; Volume: 10; Issue: 7 Linguagem: Inglês
10.2903/j.efsa.2012.2811
ISSN1831-4732
Tópico(s)Clinical Nutrition and Gastroenterology
ResumoEFSA JournalVolume 10, Issue 7 2811 OpinionOpen Access Scientific Opinion on bovine lactoferrin EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author First published: 17 July 2012 https://doi.org/10.2903/j.efsa.2012.2811Citations: 6 Panel members: Carlo V. Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen Correspondence: nda@efsa.europa.eu Acknowledgement: The Panel wishes to thank the members of the Working Group on Novel Foods: Karl-Heinz Engel, Ines Golly, Marina Heinonen, Pagona Lagiou, Rosangela Marchelli, Bevan Moseley, Monika Neuhäuser-Berthold, Annette Pöting, Seppo Salminen, Hendrik Van Loveren, Hans Verhagen and EFSA's staff member Wolfgang Gelbmann for the preparatory work on this scientific opinion Adoption date: 28 June 2012 Published date: 17 July 2012 Question number: EFSA-Q-2011-00974 On request from: European Commission AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to carry out the additional assessment for 'lactoferrin' as a food ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and objections of a scientific nature raised by Member States. Bovine lactoferrin (bLF) is a protein that occurs naturally in cow's milk. The applicant intends to market bLF that is isolated from cheese whey and skimmed milk, and purified. The applicant intends to add bLF to foods for particular nutritional uses, i.e. infant and follow-on formulae, dietary food for special medical purposes, dairy products, yoghurts and yoghurt drinks, and chewing gums. According to the applicant, the high intake estimate for infants would be 1.1 g bLF per day. For adults, the applicant's calculation estimates a mean and 97.5th percentile intake of 0.6 and 2.1 mg/kg bodyweight per day, respectively, and a mean and 97.5th percentile daily intake of about 45 mg and 150 mg, respectively. The Panel notes that the safety of bLF as a novel food ingredient has already been assessed with a favourable outcome. That evaluation was to a significant extent based on safety data on bLF produced by Morinaga. The Panel also notes that the applicant intends maximum use levels of bLF in foods which are equivalent or lower than those intended by the applicant of the previous Opinion, and that the range of foods to which it is intended to add bLF is smaller. Consequently, the estimated intake levels described for the present application are comparable for infants and lower for all other population groups. The Panel concludes that the novel food ingredient, bLF, is safe under the proposed uses and use levels. References Aisen P and Leibman A, 1972. Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta, 257, 314– 323. Brines RD and Brock JH, 1983. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim Biophys Acta, 759, 229– 235. Castellino FJ, Fish WW and Mann KG, 1970. Structural studies on bovine lactoferrin. J Biol Chem, 245, 4269– 4275. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on bovine lactoferrin. EFSA Journal 2012; 10(5):2701. [ 26 pp.]. doi:10.2903/j.efsa.2012.2701. Available online: www.efsa.europa.eu/efsajournal FSA. Food Portion Sizes, 3rd ed. Food Standards Agency (FSA), Her Majesty's Stationery Office (HMSO), London, Engl.; 2002. Kawai A, 1997. Final Report. Reverse mutation test of MONL-01 using bacteria. (Study Number 9701A). August 28, 1997. Nishimura N, 1991. Single dose oral toxicity study of monl-01 and monl-02 in rats (Study Number B-1969). Gotemba Laboratory, Bozo Research Center Inc., Setagaya-ku;, Tokyo, Japan. Nishimura N, 1997. Four-week oral repeated dose toxicity study of monl-01 in rats (Study Number B-3578). Bozo Research Center Inc., Setagaya-ku;, Tokyo, Japan. Nishimura N, 1998. Thirteen-week oral repeated dose toxicity study of monl-01 in rats (Study Number B-3579). Bozo Research Center Inc., Setagaya-ku;, Tokyo, Japan. Office for National Statistics, 2005. The National Diet and Nutrition Survey: Adults Aged 19 to 64 Years. 2000–2001 [Computer File]. Office for National Statistics, Social and Vital Statistics Division & Food Standards Agency (FSA); Colchester, Essex, UK, UK Data Archive [distributor]. SN: 5140. Paulsson MA, Svensson U, Kishore AR and Naidu AS, 1993. Thermal behavior of bovine lactoferrin in water and its relation to bacterial interaction and antibacterial activity. J Dairy Sci, 76, 3711– 3720. Pierce A, Colavizza D, Benaissa M, Maes P, Tartra A, Montreuil J and Spik G, 1991. Molecular cloning and sequence analysis of bovine lactoferrin. European Journal of Biochemistry, 196, 177– 184. Querinjean P, Masson PL and Heremans JF, 1971. Molecular weight, single-chain structure and amino acid composition of human lactoferrin. Eur J Biochem, 20, 420– 425. Shimazaki K, Kawaguchi A, Sato T, Ueda Y, Tomimura T and Shimamura S, 1993. Analysis of human and bovine milk lactoferrins by Rotofor and chromatofocusing. Int J Biochem, 25, 1653– 1658. UKDA, 1995. National Diet, Nutrition and Dental Survey of Children Aged 1 1/2 to 4 1/2 Years, 1992–1993 [computer file]. Office of Population Censuses and Surveys, Social Survey Division, Medical Research Council Centre for Human Nutrition Research, Ministry of Agriculture, Fisheries and Food (MAFF), and U.K. Department of Health. Colchester, Essex; UK Data Archive (UKDA) [distributor], 13 December 1995. SN: 3481. UKDA, 2001. National Diet Nutrition Survey: Young People Aged 4 to 18 Years, 1997. Office for National Statistics Social Survey Division, Medical Research Council Centre for Human Nutrition Research, Ministry of Agriculture, Fisheries and Food (MAFF), and Department of Health. Colchester, Essex; UK Data Archive (UKDA) [distributor], 25 January 2001. SN: 4243. Yamauchi K, Toida T, Kawai A, Nishimura S, Teraguchi S and Hayasawa H, 2000a. Mutagenicity of bovine lactoferrin in reverse mutation test. J Toxicol Sci, 25, 63– 66. Yamauchi K, Toida T, Nishimura S, Nagano E, Kusuoka O, Teraguchi S, Hayasawa H, Shimamura S and Tomita M, 2000b. 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem Toxicol, 38, 503– 512. Yoshida S and Ye X, 1991. Isolation of lactoperoxidase and lactoferrin from bovine milk rennet whey and acid whey by sulphopropyl cationexchange chromatography. Netherlands Milk and Dairy Journal, 45, 273– 280. Citing Literature Volume10, Issue7July 20122811 ReferencesRelatedInformation
Referência(s)